TACSTD2 and cancer: Therefore, lysosomes and mitochondria are considered as apparent targets for site-directed cancer therapies.22,23,26–28 Here, Pr1E11, a MAb that specifically binds to TROP-2 glycoprotein receptor type I (also known as tumorassociated calcium signal transducer protein; TACSTD2) was used as a target for TAN therapy.29 TROP-2 receptors are highly expressed in a variety of carcinomas and epithelial cancers; but less expressed in normal somatic cells.